- ►ahajournals.org A Goldin, JA Beckman, AM Schmidt, MA Creager - Circulation, 2006 - Am Heart Assoc Advanced glycation end products (AGEs) are proteins or lipids that become glycated after exposure
to sugars. AGEs are prevalent in the diabetic vasculature and contribute to the development
of atherosclerosis. The presence and accumulation of AGEs in many different cell types ... Cited by 193 - Related articles - All 7 versions
KAM Jandeleit-Dahm, C Tikellis, CM Reid, CI … - Journal of …, 2005 - journals.lww.com Recent trials have suggested that inhibitors of the renin-angiotensin system (RAS), such as
angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers
(ARBs), may reduce the incidence of new-onset diabetes in patients with or without ... Cited by 159 - Related articles - All 6 versions
JM Forbes, LTL Yee, V Thallas, M Lassila, R Candido, … - Diabetes, 2004 - Am Diabetes Assoc Advanced glycation end product (AGE) formation may contribute to the progression of
atherosclerosis, particularly in diabetes. The present study explored atherosclerosis in
streptozotocin-induced diabetic apolipoprotein E–deficient (apoE−/−) mice that were ... Cited by 137 - Related articles - BL Direct - All 9 versions
PJ Thornalley - Archives of Biochemistry and Biophysics, 2003 - Elsevier Aminoguanidine (AG) is a prototype therapeutic agent for the prevention of formation of advanced
glycation endproducts. It reacts rapidly with α,β-dicarbonyl compounds such as
methylglyoxal, glyoxal, and 3-deoxyglucosone to prevent the formation of advanced ... Cited by 125 - Related articles - All 4 versions
S Yamagishi, T Imaizumi - Current pharmaceutical design, 2005 - ingentaconnect.com Abstract: Diabetic vascular complication is a leading cause of end-stage renal failure, acquired
blindness, a variety of neuropathies and accelerated atherosclerosis, which could account for
disabilities and high mortality rates in patients with diabetes. Recent large prospective ... Cited by 123 - Related articles - All 3 versions
- ►endojournals.org BF Schrijvers, AS De Vriese, A Flyvbjerg - Endocrine reviews, 2004 - Endocrine Soc At present, diabetic kidney disease affects about 15–25% of type 1 and 30–40% of type 2 diabetic
patients. Several decades of extensive research has elucidated various pathways to be implicated
in the development of diabetic kidney disease. This review focuses on the metabolic ... Cited by 122 - Related articles - All 5 versions
- ►morelife.org [PDF] S Rahbar, JL Figarola - Archives of Biochemistry and Biophysics, 2003 - Elsevier A number of natural or synthetic compounds as AGE inhibitors have been proposed, discovered
or currently being advanced by others and us. We have identified two new classes of aromatic
compounds; aryl- (and heterocyclic) ureido and aryl (and heterocyclic) carboxamido ... Cited by 111 - Related articles - BL Direct - All 10 versions
